{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:56:53Z","timestamp":1779119813931,"version":"3.51.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"DOI":"10.1007\/s11154-022-09753-6","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T06:02:44Z","timestamp":1663653764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy"],"prefix":"10.1007","author":[{"given":"Anahid","family":"Hamidianjahromi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-607X","authenticated-orcid":false,"given":"Nicholas A","family":"Tritos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"9753_CR1","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3389\/fneur.2018.01041","volume":"9","author":"PJ Garcia-Ruiz","year":"2018","unstructured":"Garcia-Ruiz PJ. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. Front Neurol. 2018;9:1041. https:\/\/doi.org\/10.3389\/fneur.2018.01041.","journal-title":"Front Neurol"},{"key":"9753_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3389\/fneur.2018.00654","volume":"9","author":"A Martini","year":"2018","unstructured":"Martini A, et al. Impulse Control Disorder in Parkinson\u2019s Disease: A Meta-Analysis of Cognitive, Affective, and Motivational Correlates. Front Neurol. 2018;9:654. https:\/\/doi.org\/10.3389\/fneur.2018.00654.","journal-title":"Front Neurol"},{"issue":"2","key":"9753_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","volume":"34","author":"D Dang","year":"2011","unstructured":"Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011;34(2):66\u201370. https:\/\/doi.org\/10.1097\/WNF.0b013e31820d6699.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"9753_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/art.21191","volume":"52","author":"AJ Holman","year":"2005","unstructured":"Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52(8):2495\u2013505. https:\/\/doi.org\/10.1002\/art.21191.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"9753_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2169\/internalmedicine.4836-20","volume":"60","author":"C Ishida","year":"2021","unstructured":"Ishida C, et al. Effectiveness of Levodopa in Patients with Multiple System Atrophy and Associated Clinicopathological Features. Intern Med. 2021;60(3):367\u201372. https:\/\/doi.org\/10.2169\/internalmedicine.4836-20.","journal-title":"Intern Med"},{"issue":"3","key":"9753_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ana.410130308","volume":"13","author":"JA Jackson","year":"1983","unstructured":"Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol. 1983;13(3):273\u20138. https:\/\/doi.org\/10.1002\/ana.410130308.","journal-title":"Ann Neurol"},{"issue":"2","key":"9753_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","volume":"17","author":"M Barake","year":"2014","unstructured":"Barake M, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014;17(2):150\u20136. https:\/\/doi.org\/10.1007\/s11102-013-0480-6.","journal-title":"Pituitary"},{"issue":"6","key":"9753_CR8","doi-asserted-by":"publisher","first-page":"R287","DOI":"10.1530\/EJE-18-0667","volume":"179","author":"M Barake","year":"2018","unstructured":"Barake M, Klibanski A, Tritos NA, MANAGEMENT OF ENDOCRINE DISEASE. Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry? Eur J Endocrinol. 2018;179(6):R287. https:\/\/doi.org\/10.1530\/EJE-18-0667.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9753_CR9","doi-asserted-by":"publisher","first-page":"e20428","DOI":"10.5812\/ijhrba.20428","volume":"3","author":"NM Bakhshani","year":"2014","unstructured":"Bakhshani NM. Impulsivity: a predisposition toward risky behaviors. Int J High Risk Behav Addict. 2014;3(2):e20428. https:\/\/doi.org\/10.5812\/ijhrba.20428.","journal-title":"Int J High Risk Behav Addict"},{"issue":"4","key":"9753_CR10","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10899-017-9683-5","volume":"33","author":"NS Chowdhury","year":"2017","unstructured":"Chowdhury NS, et al. Pathological Gambling and Motor Impulsivity: A Systematic Review with Meta-Analysis. J Gambl Stud. 2017;33(4):1213\u201339. https:\/\/doi.org\/10.1007\/s10899-017-9683-5.","journal-title":"J Gambl Stud"},{"issue":"6","key":"9753_CR11","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/hbm.22344","volume":"35","author":"F Antonelli","year":"2014","unstructured":"Antonelli F, et al. Dopamine-agonists and impulsivity in Parkinson\u2019s disease: impulsive choices vs. impulsive actions. Hum Brain Mapp. 2014;35(6):2499\u2013506. https:\/\/doi.org\/10.1002\/hbm.22344.","journal-title":"Hum Brain Mapp"},{"key":"9753_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","volume":"133","author":"D Weintraub","year":"2017","unstructured":"Weintraub D, Claassen DO. Impulse Control and Related Disorders in Parkinson\u2019s Disease. Int Rev Neurobiol. 2017;133:679\u2013717. https:\/\/doi.org\/10.1016\/bs.irn.2017.04.006.","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"9753_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/wps.20050","volume":"12","author":"DA Regier","year":"2013","unstructured":"Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2):92\u20138. https:\/\/doi.org\/10.1002\/wps.20050.","journal-title":"World Psychiatry"},{"issue":"6","key":"9753_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617\u201327. https:\/\/doi.org\/10.1001\/archpsyc.62.6.617.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"9753_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","volume":"35","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261\u20135. https:\/\/doi.org\/10.1097\/WNF.0b013e31826e6e6d.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"9753_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens J, et al. Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord. 2013;28(3):327\u201333. https:\/\/doi.org\/10.1002\/mds.25291.","journal-title":"Mov Disord"},{"issue":"8","key":"9753_CR17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, et al. Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840\u20134. https:\/\/doi.org\/10.1136\/jnnp-2013-306787.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"9753_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1468-1331.2008.02081.x","volume":"15","author":"A Imamura","year":"2008","unstructured":"Imamura A, et al. Medications used to treat Parkinson\u2019s disease and the risk of gambling. Eur J Neurol. 2008;15(4):350\u20134. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02081.x.","journal-title":"Eur J Neurol"},{"key":"9753_CR19","doi-asserted-by":"publisher","unstructured":"Weintraub D, et al., Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol, 2010. 67(5): p. 589 \u2013 95. https:\/\/doi.org\/10.1001\/archneurol.2010.65.","DOI":"10.1001\/archneurol.2010.65"},{"key":"9753_CR20","doi-asserted-by":"publisher","unstructured":"Voon V, et al., Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology, 2010. 207(4): p. 645 \u2013 59. https:\/\/doi.org\/10.1001\/archneurol.2010.65.","DOI":"10.1001\/archneurol.2010.65"},{"issue":"4","key":"9753_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","volume":"19","author":"M Davie","year":"2007","unstructured":"Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci. 2007;19(4):473\u20134. https:\/\/doi.org\/10.1176\/jnp.2007.19.4.473.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"9753_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","volume":"190","author":"H Falhammar","year":"2009","unstructured":"Falhammar H, Yarker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust. 2009;190(2):97. https:\/\/doi.org\/10.5694\/j.1326-5377.2009.tb02289.x.","journal-title":"Med J Aust"},{"issue":"5","key":"9753_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, et al. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179\u201381. https:\/\/doi.org\/10.1097\/WNF.0b013e3182281b2f.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"9753_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, et al. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863\u20138. https:\/\/doi.org\/10.1111\/cen.12375.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"9753_CR25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","volume":"62","author":"E Celik","year":"2018","unstructured":"Celik E, et al. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine. 2018;62(3):692\u2013700. https:\/\/doi.org\/10.1007\/s12020-018-1744-8.","journal-title":"Endocrine"},{"issue":"7","key":"9753_CR26","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, et al. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. J Clin Endocrinol Metab. 2019;104(7):2527\u201334. https:\/\/doi.org\/10.1210\/jc.2018-02202.","journal-title":"J Clin Endocrinol Metab"},{"key":"9753_CR27","doi-asserted-by":"publisher","first-page":"579606","DOI":"10.3389\/fendo.2020.579606","volume":"11","author":"JM Hinojosa-Amaya","year":"2020","unstructured":"Hinojosa-Amaya JM, et al. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Front Endocrinol (Lausanne). 2020;11:579606. https:\/\/doi.org\/10.3389\/fendo.2020.579606.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9753_CR28","doi-asserted-by":"publisher","first-page":"101356","DOI":"10.1016\/j.ghir.2020.101356","volume":"55","author":"HM Ozkaya","year":"2020","unstructured":"Ozkaya HM, et al. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth Horm IGF Res. 2020;55:101356. https:\/\/doi.org\/10.1016\/j.ghir.2020.101356.","journal-title":"Growth Horm IGF Res"},{"key":"9753_CR29","doi-asserted-by":"publisher","unstructured":"De Sousa SMC, et al., Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. J Clin Endocrinol Metab, 2020. 105(3). https:\/\/doi.org\/10.1210\/clinem\/dgz076.","DOI":"10.1210\/clinem\/dgz076"},{"issue":"8","key":"9753_CR30","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","volume":"44","author":"G Beccuti","year":"2021","unstructured":"Beccuti G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest. 2021;44(8):1699\u2013706. https:\/\/doi.org\/10.1007\/s40618-020-01478-0.","journal-title":"J Endocrinol Invest"},{"issue":"47","key":"9753_CR31","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.3346\/jkms.2018.33.e300","volume":"33","author":"JW Han","year":"2018","unstructured":"Han JW, et al. Psychiatric Manifestation in Patients with Parkinson\u2019s Disease. J Korean Med Sci. 2018;33(47):e300. https:\/\/doi.org\/10.3346\/jkms.2018.33.e300.","journal-title":"J Korean Med Sci"},{"issue":"15","key":"9753_CR32","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/mds.22589","volume":"24","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson\u2019s disease. Mov Disord. 2009;24(15):2175\u201386. https:\/\/doi.org\/10.1002\/mds.22589.","journal-title":"Mov Disord"},{"key":"9753_CR33","doi-asserted-by":"publisher","unstructured":"Weintraub D, Papay K, Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology, 2013. 80(2): p. 176 \u2013 80. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b915c.","DOI":"10.1212\/WNL.0b013e31827b915c"},{"issue":"12","key":"9753_CR34","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930\u20133. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5262.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"9753_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.biopsych.2009.09.021","volume":"67","author":"C Eisenegger","year":"2010","unstructured":"Eisenegger C, et al. Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. Biol Psychiatry. 2010;67(8):702\u20136. https:\/\/doi.org\/10.1016\/j.biopsych.2009.09.021.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"9753_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/sjop.12113","volume":"55","author":"DA Ziegler","year":"2014","unstructured":"Ziegler DA, et al. Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms. Scand J Psychol. 2014;55(3):278\u201386. https:\/\/doi.org\/10.1111\/sjop.12113.","journal-title":"Scand J Psychol"},{"key":"9753_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12883-015-0316-2","volume":"15","author":"S Zainal Abidin","year":"2015","unstructured":"Zainal Abidin S, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson\u2019s disease patients. BMC Neurol. 2015;15:59. https:\/\/doi.org\/10.1186\/s12883-015-0316-2.","journal-title":"BMC Neurol"},{"key":"9753_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2016.06.005","volume":"30","author":"S Krishnamoorthy","year":"2016","unstructured":"Krishnamoorthy S, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson\u2019s disease patients. Parkinsonism Relat Disord. 2016;30:13\u20137. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.06.005.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"9753_CR39","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/mds.22678","volume":"24","author":"JY Lee","year":"2009","unstructured":"Lee JY, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson\u2019s disease. Mov Disord. 2009;24(12):1803\u201310. https:\/\/doi.org\/10.1002\/mds.22678.","journal-title":"Mov Disord"},{"key":"9753_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.parkreldis.2018.01.010","volume":"49","author":"XH Castro-Mart\u00ednez","year":"2018","unstructured":"Castro-Mart\u00ednez XH, et al. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. Parkinsonism Relat Disord. 2018;49:100\u20133. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.01.010.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"9753_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.parkreldis.2011.10.019","volume":"18","author":"A Vallelunga","year":"2012","unstructured":"Vallelunga A, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson\u2019s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2012;18(4):397\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.10.019.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"9753_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mdc3.13128","volume":"8","author":"P Parra-D\u00edaz","year":"2021","unstructured":"Parra-D\u00edaz P, et al. Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review. Mov Disord Clin Pract. 2021;8(1):25\u201332. https:\/\/doi.org\/10.1002\/mdc3.13128.","journal-title":"Mov Disord Clin Pract"},{"issue":"8","key":"9753_CR43","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1055\/s-0031-1281580","volume":"79","author":"M Gahr","year":"2011","unstructured":"Gahr M, Connemann BJ, Sch\u00f6nfeldt-Lecuona CJ. [Pathological gambling induced by dopamine agonists]. Fortschr Neurol Psychiatr. 2011;79(8):470\u20134. https:\/\/doi.org\/10.1055\/s-0031-1281580.","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"4","key":"9753_CR44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.psym.2012.10.002","volume":"54","author":"S Almanzar","year":"2013","unstructured":"Almanzar S, Zapata-Vega MI, Raya JA. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics. 2013;54(4):387\u201391. https:\/\/doi.org\/10.1016\/j.psym.2012.10.002.","journal-title":"Psychosomatics"},{"issue":"2","key":"9753_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7861\/clinmedicine.14-2-205","volume":"14","author":"VS Premaratne","year":"2014","unstructured":"Premaratne VS, Saeger I, Macdonald BK. Lesson of the month (1): cabergoline - \u2018i eat funny on that\u2019. Clin Med (Lond). 2014;14(2):205\u20137. https:\/\/doi.org\/10.7861\/clinmedicine.14-2-205.","journal-title":"Clin Med (Lond)"},{"issue":"6","key":"9753_CR46","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/cen.13339","volume":"86","author":"C Bulwer","year":"2017","unstructured":"Bulwer C, et al. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clin Endocrinol (Oxf). 2017;86(6):862\u20134. https:\/\/doi.org\/10.1111\/cen.13339.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"9753_CR47","doi-asserted-by":"publisher","first-page":"R88-r94","DOI":"10.1530\/EC-18-0030","volume":"7","author":"AP Athanasoulia-Kaspar","year":"2018","unstructured":"Athanasoulia-Kaspar AP, Popp KH, Stalla GK. Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocr Connect. 2018;7(2):R88-r94. https:\/\/doi.org\/10.1530\/EC-18-0030.","journal-title":"Endocr Connect"},{"issue":"5","key":"9753_CR48","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","volume":"36","author":"SK Thondam","year":"2013","unstructured":"Thondam SK, et al. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin Neuropharmacol. 2013;36(5):170\u20132. https:\/\/doi.org\/10.1097\/WNF.0b013e31829fc165.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"9753_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","volume":"22","author":"X Ke","year":"2022","unstructured":"Ke X, et al. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study. BMC Endocr Disord. 2022;22(1):97. https:\/\/doi.org\/10.1186\/s12902-022-01009-3.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"9753_CR50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","volume":"55","author":"SM De Sousa","year":"2017","unstructured":"De Sousa SM, et al. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017;55(2):618\u201324. https:\/\/doi.org\/10.1007\/s12020-016-1088-1.","journal-title":"Endocrine"},{"key":"9753_CR51","doi-asserted-by":"publisher","first-page":"108278","DOI":"10.1016\/j.neuropharm.2020.108278","volume":"179","author":"V Rawji","year":"2020","unstructured":"Rawji V, et al. Ropinirole, a dopamine agonist with high D(3) affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults. Neuropharmacology. 2020;179:108278. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108278.","journal-title":"Neuropharmacology"},{"issue":"8","key":"9753_CR52","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1162\/jocn_a_00241","volume":"24","author":"SA Wylie","year":"2012","unstructured":"Wylie SA, et al. Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. J Cogn Neurosci. 2012;24(8):1709\u201324. https:\/\/doi.org\/10.1162\/jocn_a_00241.","journal-title":"J Cogn Neurosci"},{"key":"9753_CR53","doi-asserted-by":"publisher","unstructured":"Mostofsky SH, Simmonds DJ. Response inhibition and response selection: two sides of the same coin. J Cogn Neurosci, 2008. 20(5): p. 751 \u2013 61. https:\/\/doi.org\/10.1162\/jocn.2008.20500.","DOI":"10.1162\/jocn.2008.20500"},{"issue":"4","key":"9753_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1017\/S0033291705006409","volume":"36","author":"MA Bellgrove","year":"2006","unstructured":"Bellgrove MA, et al. Lateralized deficit of response inhibition in early-onset schizophrenia. Psychol Med. 2006;36(4):495\u2013505. https:\/\/doi.org\/10.1017\/S0033291705006409.","journal-title":"Psychol Med"},{"issue":"11","key":"9753_CR55","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1176\/appi.ajp.158.11.1884","volume":"158","author":"J Crosbie","year":"2001","unstructured":"Crosbie J, Schachar R. Deficient inhibition as a marker for familial ADHD. Am J Psychiatry. 2001;158(11):1884\u201390. https:\/\/doi.org\/10.1176\/appi.ajp.158.11.1884.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"9753_CR56","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11065-007-9034-x","volume":"17","author":"H Garavan","year":"2007","unstructured":"Garavan H, Hester R. The role of cognitive control in cocaine dependence. Neuropsychol Rev. 2007;17(3):337\u201345. https:\/\/doi.org\/10.1007\/s11065-007-9034-x.","journal-title":"Neuropsychol Rev"},{"issue":"1","key":"9753_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association. Drug Saf. 2018;41(1):19\u201375. https:\/\/doi.org\/10.1007\/s40264-017-0590-6.","journal-title":"Drug Saf"},{"issue":"1","key":"9753_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0023-9690(80)90021-1","volume":"11","author":"JV Solnick","year":"1980","unstructured":"Solnick JV, et al. An experimental analysis of impulsivity and impulse control in humans. Learn Motiv. 1980;11(1):61\u201377. https:\/\/doi.org\/10.1016\/0023-9690(80)90021-1.","journal-title":"Learn Motiv"},{"issue":"4","key":"9753_CR59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P. Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183\u20139. https:\/\/doi.org\/10.1002\/syn.21805.","journal-title":"Synapse"},{"issue":"4","key":"9753_CR60","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3233\/BEN-2012-120266","volume":"26","author":"S Balarajah","year":"2013","unstructured":"Balarajah S, Cavanna AE. The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol. 2013;26(4):237\u201344. https:\/\/doi.org\/10.3233\/BEN-2012-120266.","journal-title":"Behav Neurol"},{"key":"9753_CR61","doi-asserted-by":"publisher","unstructured":"Matusiewicz AK, Reynolds B, Lejuez C. Assessment Instruments for Impulsivity and Impulse Control Disorders, The Oxford Handbook of Impulse Control Disorders. 2011, Oxford University Press. p.\u00a00. https:\/\/doi.org\/10.1093\/oxfordhb\/9780195389715.013.0141.","DOI":"10.1093\/oxfordhb\/9780195389715.013.0141"},{"issue":"2","key":"9753_CR62","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mds.24023","volume":"27","author":"D Weintraub","year":"2012","unstructured":"Weintraub D, et al. Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s Disease-Rating Scale. Mov Disord. 2012;27(2):242\u20137. https:\/\/doi.org\/10.1002\/mds.24023.","journal-title":"Mov Disord"},{"issue":"4","key":"9753_CR63","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1022119414440","volume":"21","author":"B Meyer","year":"1999","unstructured":"Meyer B, Johnson SL, Carver CS. Exploring Behavioral Activation and Inhibition Sensitivities Among College Students at Risk for Bipolar Spectrum Symptomatology. J Psychopathol Behav Assess. 1999;21(4):275\u201392. https:\/\/doi.org\/10.1023\/A:1022119414440.","journal-title":"J Psychopathol Behav Assess"},{"issue":"6","key":"9753_CR64","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::aid-jclp2270510607>3.0.co;2-1","volume":"51","author":"JH Patton","year":"1995","unstructured":"Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768\u201374. https:\/\/doi.org\/10.1002\/1097-4679(199511)51:6<768::aid-jclp2270510607>3.0.co;2-1.","journal-title":"J Clin Psychol"},{"issue":"1","key":"9753_CR65","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/10720162.2011.555709","volume":"18","author":"RC Reid","year":"2011","unstructured":"Reid RC, Garos S, Carpenter BN. Reliability, Validity, and Psychometric Development of the Hypersexual Behavior Inventory in an Outpatient Sample of Men. Sex Addict Compulsivity. 2011;18(1):30\u201351. https:\/\/doi.org\/10.1080\/10720162.2011.555709.","journal-title":"Sex Addict Compulsivity"},{"issue":"3","key":"9753_CR66","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1556\/JBA.1.2012.001","volume":"1","author":"RC Reid","year":"2012","unstructured":"Reid RC, Garos S, Fong T. Psychometric development of the hypersexual behavior consequences scale. J Behav Addict. 2012;1(3):115\u201322. https:\/\/doi.org\/10.1556\/JBA.1.2012.001.","journal-title":"J Behav Addict"},{"issue":"9","key":"9753_CR67","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1176\/ajp.144.9.1184","volume":"144","author":"HR Lesieur","year":"1987","unstructured":"Lesieur HR, Blume SB. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry. 1987;144(9):1184\u20138. https:\/\/doi.org\/10.1176\/ajp.144.9.1184.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"9753_CR68","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.neuroimage.2008.05.046","volume":"42","author":"H Rao","year":"2008","unstructured":"Rao H, et al. Neural correlates of voluntary and involuntary risk taking in the human brain: an fMRI Study of the Balloon Analog Risk Task (BART). NeuroImage. 2008;42(2):902\u201310. https:\/\/doi.org\/10.1016\/j.neuroimage.2008.05.046.","journal-title":"NeuroImage"},{"key":"9753_CR69","doi-asserted-by":"publisher","unstructured":"Reynolds B, Schiffbauer R, Measuring state changes in human delay discounting: an experiential discounting task. Behav Processes, 2004. 67(3): p.\u00a0343 \u2013 56. https:\/\/doi.org\/10.1016\/j.beproc.2004.06.003.","DOI":"10.1016\/j.beproc.2004.06.003"},{"issue":"7","key":"9753_CR70","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip J, et al. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94(7):2428\u201336. https:\/\/doi.org\/10.1210\/jc.2008-2103.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09753-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-022-09753-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09753-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T16:41:17Z","timestamp":1664988077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-022-09753-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":70,"alternative-id":["9753"],"URL":"https:\/\/doi.org\/10.1007\/s11154-022-09753-6","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"26 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used to support this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards and funding information"}},{"value":"NAT has received institution-directed research support from Ipsen and Novartis and has served as an occasional consultant to Novo Nordisk and Pfizer. AH has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement\/conflict of interest"}},{"value":"Informed consent and ethical approval were not obtained since the manuscript does not report on primary data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and ethical approval"}}]}}